CancersBiophysicsPeer-reviewed journal article
Altered Mechanobiology of PDAC Cells with Acquired Chemoresistance to Gemcitabine and Paclitaxel.
Alessandro GregoriiD, Cecilia BergonziniiD, Mjriam CapulaiD, Rick Rodrigues de MercadoiD, Erik H.J. DaneniD, Elisa GiovannettiiD, Thomas SchmidtiD
Abstract
BackgroundPancreatic ductal adenocarcinoma (PDAC) acquired resistance to chemotherapy poses a major limitation to patient survival. Despite understanding of some biological mechanisms of chemoresistance, much of those mechanisms remain to be uncovered. Mechanobiology, which studies physical properties of cells, holds promise as a potential target for addressing challenges of chemoresistance in PDAC. Therefore, we here in an initial step, assessed the altered mechanobiology of PDAC cells with acquired chemoresistance to gemcitabine and paclitaxel. MethodsFive PDAC cell lines and six stably-resistant subclones were assessed for force generation on elastic micropillar arrays. Those measurements of mechanical phenotype were complemented by single-cell motility and invasion in collagen matrix were investigated using 2D models and 3D extracellular matrix-mimetic, respectively. Further the nuclear translocation of Yes-associted protein (YAP), as a measure of active mechanical status, was compared, and biomarkers of the epithelial-to-mesenchymal transition (EMT) were evaluated using RT-PCR. ResultsPDAC cells with acquired chemoresistance exert higher traction forces than their parental/wild-type (WT) cells. In 2D, single-cell motility was altered for all chemoresistant cells, with a cell-type specific pattern. In 3D, spheroids of chemoresistant PDAC cells were able to invade the matrix, and remodel collagen more than their WT clones. However, YAP nuclear translocation and EMT were not significantly altered in relation to changes in other physical parameters. ConclusionThis is the first study to investigate and report on the altered mechanobiological features for PDAC cells that have acquired chemoresistance. A better understanding of mechanical features could help in identifying future targets to overcome chemoresistance in PDAC.
- Citations
- 7
- FWCI
- 1.02
- Field percentile
- top 31%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Engineered extracellular matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids
B. L. LeSavage, A. E. Gilchrist, … S. C. Heilshorn·bioRxiv·Apr 22, 2022
- ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells
C. Bergonzini, A. Gregori, … E. H. J. Danen·bioRxiv·May 30, 2023
- Pancreatic Stellate Cells Secrete Deoxycytidine Conferring Resistance to Gemcitabine in PDAC
S. Dalin, M. R. Sullivan, … M. T. Hemann·Cancer ResearchPeer-reviewed·Nov 15, 2019
- Mechanobiology-guided drug repurposing identifies budesonide as an inhibitor of stiffness-induced PDAC aggressiveness
Simone Mas, Marco Cristiano, … Cristina D’Aniello·bioRxiv·Jul 20, 2026
- Tumor Cell Death Drives Tumor-Promoting IL-6+ iCAF formation via P2X7-activation
Ciarán McDonnell, Valeriya V. Zinina, … Mark R. Schmitt·bioRxiv·Mar 20, 2026
- A trajectory-coupled network bottleneck governs gemcitabine resistance in 3D PDAC tissue models
MARYAM ALMASI, Jesús Guillermo Nieves Pereira, … Johannes Balkenhol·bioRxiv·Mar 26, 2026